Treatment of 30 cases of vitiligo by cupping method plus external application of Chinese herbs

在皮损区拔罐,然后外涂中药治疗白癜风患者30例,对照组予西药治疗,3个疗程后,治疗组总有效率96.7%,对照组总有效率76.7%.治疗组疗效好于对照组(P＜0.05).     

Treatment of 30 cases of rheumatoid arthritis by needle-warming therapy

取双侧肾俞、足三里和曲池,进行温针,并配合内服中药治疗类风湿性关节炎患者30例,以西药常规治疗30例为对照.治疗3个月后,两组有效率分别为86.7%和60.0%,疗效差异有统计意义(P＜0.05).     

Clinical observation on scapulohumeral periarthritis treated by Tuina and SSP meridian therapeutic apparatus

目的:观察推拿结合经脉治疗仪治疗肩周炎的疗效.方法:观察组采用推拿结合日本产SSP经脉治疗仪治疗肩周炎患者35例.对照组单纯用经脉治疗仪治疗肩周炎患者30例.结果:观察组与对照组对肩周炎的治疗都有一定效果.但观察组的治愈率与对照组相比有明显差距(P＜0.01),观察组对肩周炎的治愈率明显高于对照组.结论:经脉治疗仪结合推拿是治疗肩周炎的一种有效方法.     

Treatment of 25 cases of obstruction of Qi in the chest by Tuina

应用一指禅手法为主治疗25例胸痹患者,结果显示推拿对胸痹患者的各种临床症状均有缓解作用,治愈10例,好转14例,无效1例.     

Treatment of Acute Lumbar Sprain with Single Acupoint： A RCT

目的:评价单一穴位治疗急性腰扭伤的治疗效果.方法:根据统一的诊断标准,在多个临床中心进行随机对照研究.全部病例320例经随机数字表法分为针刺后溪穴观察组和针刺腰痛点对照组.对患者的疼痛程度分别由医师和患者进行评分.结果:治疗2个疗程后,观察组和对照组近期有效率分别为89.4%和82.5%,远期有效率分别为95.6%和93.5%.经Ridit分析,近期疗效差异有统计意义(P<0.05),远期疗效差异无统计意义(P>0.05).结论:针刺单一穴位治疗急性腰扭伤疗效确切,取穴简便,后溪穴疗效好于腰痛点.     

Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

PURPOSE AND EXPERIMENTAL DESIGN: The stem cell factor/KIT receptor loop may represent a novel target for molecular-based therapies of Ewing tumor. We analyzed the in vitro impact of KIT blockade by imatinib in Ewing tumor cell lines. RESULTS: KIT expression was detected in 4 of 4 Ewing tumor cell lines and in 49 of 110 patient samples (44.5%) by immunohistochemistry and/or Western blot analysis. KIT expression was stronger in Ewing tumors showing EWS-FLI1 nontype 1 fusions. Despite absence of c-kit mutations, constitutive and ligand-inducible phosphorylation of KIT was found in all tumor cell lines, indicating an active receptor. Treatment with KIT tyrosine kinase inhibitor imatinib (0.5-20 micro M) induced down-regulation of KIT phosphorylation and dose response inhibition of cell proliferation (IC(50), 12-15 micro M). However, imatinib administered alone at doses close to IC(50) for growth inhibition (10 micro M) did not induce a significant increase in apoptosis. We then analyzed if blockade of KIT loop through imatinib (10 micro M) was able to increase the antitumor in vitro effect of doxorubicin (DXR) and vincristine (VCR), drugs usually used in Ewing tumor treatment. Addition of imatinib decreased in 15-20 and 15-36% of the proliferative rate of Ewing tumor cells exposed to DXR and VCR, respectively, and increased in 15 and 30% of the apoptotic rate of Ewing tumor cells exposed to the same drugs. CONCLUSIONS: Inhibition of Ewing tumor cell proliferation by imatinib is mediated through blockade of KIT receptor signaling. Inhibition of KIT increases sensitivity of these cells to DXR and VCR. This study supports a potential role for imatinib in the treatment of Ewing tumor.     

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.     

卵巢癌高频转移细胞模型中nm23-H1基因表达的相关性研究

目的 筛选高频转移卵巢恶性肿瘤细胞，研究不同转移潜能的细胞和nm23的相关性。方法 通过反复动物接种和体外培养，观察动物肺转移状况，筛选高频转移细胞株，比较原发肿瘤和转移肿瘤的特征，并应用Northera-blot方法测定各类肿瘤细胞nm23 mRNA表达水平。结果 8株卵巢恶性肿瘤细胞中4株有较高转移潜能。多次培养接种可筛选出高频转移细胞亚群。测定各类细胞nm23 mRNA表达水平与肿瘤转移特性呈负相关。结论 由基因分子水平决定的肿瘤转移趋势在不同肿瘤种类及细胞亚群中有明显差异；卵巢癌中nm23 mRNA和蛋白的表达与其转移能力的降低有密切关系，可作为判定卵巢癌预后的敏感指标。     

人前列腺癌细胞PC-3M亚系u-PAR基因表达的分析

目的 为研究与人前列腺癌细胞(PC-3M)侵袭能力相关的靶分子。方法 采用有限稀释法分离单克隆细胞株，并应用单层细胞侵袭等实验鉴定各亚系的体外侵袭能力；借助RT-PCR和免疫组化的方法，分别在转录和翻译水平检测5株侵袭能力不同的PC-3M亚系尿激酶型纤溶酶原激活物受体(u-PAR)的表达。结果 高侵袭亚系u-PAR基因mRNA的表达和蛋白质水平均明显高于低侵袭亚系。结论 PC-3M亚系u-PAR的高表达与其较强的侵袭能力密切相关，而u-PAR可能是抑制高侵袭亚系侵袭效应的一个重要靶分子。     

Continuous care in the cancer patient: palliative care in the 21<Superscript>st</Superscript> century

Continuous care for the cancer patient is an open concept that is not only applicable only to the terminal stage. Such a simplification could generate inequities of therapy and discrimination. Historically, oncology services have been structured as networks dispensing chemotherapy and radiotherapy rather than services dedicated to the integrated care of the cancer patient. This situation has changed in a continuous and progressive manner over the past few years, as reflected in the latest Spanish Libro Blanco de Oncología. We are still far from reaching the optimum level of integrated care, possibly because we have not, as yet, achieved services that are structured and appropriate for the care-needs of the patient and, perhaps, to the lack of the necessary personnel. We must always make sure that cancer patients receive the best possible treatment, irrespective of whet-her the disease is in relapse. Oncologists must not “give up”, indicating that, in addition to using the most effective anticancer treatments available, they should deploy their best knowledge and experience to control the symptoms of cancer while providing psycho-social help to the patient and family. This is best conducted with a communication that is adjusted to the changing needs of the patient over the longterm clinical process, and should be provided by a multidisciplinary team, according to the needs of the patient and the family. Within a program of integrated care, it is possible to coordinate the existing care structures without creating parallel health networks so as to cover the needs of the greatest number of cancer patients in advanced stage of the disease.